Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Decreased basal ganglia and thalamic iron in early psychotic spectrum disorders are associated with increased psychotic and schizotypal symptoms

Abstract

Iron deficits have been reported as a risk factor for psychotic spectrum disorders (PSD). However, examinations of brain iron in PSD remain limited. The current study employed quantitative MRI to examine iron content in several iron-rich subcortical structures in 49 young adult individuals with PSD (15 schizophrenia, 17 schizoaffective disorder, and 17 bipolar disorder with psychotic features) compared with 35 age-matched healthy controls (HC). A parametric approach based on a two-pool magnetization transfer model was applied to estimate longitudinal relaxation rate (R1), which reflects both iron and myelin, and macromolecular proton fraction (MPF), which is specific to myelin. To describe iron content, a synthetic effective transverse relaxation rate (R2*) was modeled using a linear fitting of R1 and MPF. PSD patients compared to HC showed significantly reduced R1 and synthetic R2* across examined regions including the pallidum, ventral diencephalon, thalamus, and putamen areas. This finding was primarily driven by decreases in the subgroup with schizophrenia, followed by schizoaffective disorder. No significant group differences were noted for MPF between PSD and HC while for regional volume, significant reductions in patients were only observed in bilateral caudate, suggesting that R1 and synthetic R2* reductions in schizophrenia and schizoaffective patients likely reflect iron deficits that either occur independently or precede structural and myelin changes. Subcortical R1 and synthetic R2* were also found to be inversely related to positive symptoms within the PSD group and to schizotypal traits across the whole sample. These findings that decreased iron in subcortical regions are associated with PSD risk and symptomatology suggest that brain iron deficiencies may play a role in PSD pathology and warrant further study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: T1w MPRAGE image and R1, MPF and R2* parametric maps of an example HC participant.
Fig. 2: HC and PSD group differences in quantitative MRI measures.
Fig. 3: HC and PSD diagnostic subgroup differences in quantitative MRI measures.
Fig. 4: Partial plots of the relationship between synthetic R2* in left thalamus and the SIS, SANS, and SAPS scores.

Similar content being viewed by others

References

  1. Guloksuz S, van Os J. The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychological Med. 2018;48:229–44.

    CAS  Google Scholar 

  2. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748–51.

    PubMed  Google Scholar 

  3. Ellison-Wright I, Bullmore E. Anatomy of bipolar disorder and schizophrenia: A meta-analysis. Schizophrenia Res. 2010;117:1–12.

    Google Scholar 

  4. van Erp TG, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA, et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry. 2016;21:547–53.

    PubMed  Google Scholar 

  5. Morris CM, Candy JM, Oakley AE, Bloxham CA, Edwardson JA. Histochemical distribution of non-haem iron in the human brain. Acta Anat. 1992;144:235–57.

    CAS  PubMed  Google Scholar 

  6. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958;3:41–51.

    CAS  PubMed  Google Scholar 

  7. Ogg RJ, Steen RG. Age-related changes in brain T1 are correlated with iron concentration. Magn Reson Med. 1998;40:749–53.

    CAS  PubMed  Google Scholar 

  8. Larsen B, Bourque J, Moore TM, Adebimpe A, Calkins ME, Elliott MA, et al. Longitudinal Development of Brain Iron Is Linked to Cognition in Youth. J Neurosci. 2020;40:1810–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Peterson ET, Kwon D, Luna B, Larsen B, Prouty D, De Bellis MD, et al. Distribution of brain iron accrual in adolescence: Evidence from cross-sectional and longitudinal analysis. Hum Brain Mapp. 2019;40:1480–95.

    PubMed  Google Scholar 

  10. Pivina L, Semenova Y, Doşa MD, Dauletyarova M, Bjørklund G. Iron Deficiency, Cognitive Functions, and Neurobehavioral Disorders in Children. J Mol Neurosci. 2019;68:1–10.

    CAS  PubMed  Google Scholar 

  11. Spence H, McNeil CJ, Waiter GD. The impact of brain iron accumulation on cognition: A systematic review. PloS one. 2020;15:e0240697–e0240697.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Lozoff B. Early iron deficiency has brain and behavior effects consistent with dopaminergic dysfunction. J Nutr. 2011;141:740S–746S.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Kim J, Wessling-Resnick M. Iron and mechanisms of emotional behavior. J Nutr Biochem. 2014;25:1101–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Georgieff MK. Iron assessment to protect the developing brain. Am J Clin Nutr. 2017;106:1588S–1593S.

    PubMed  PubMed Central  Google Scholar 

  15. Hect JL, Daugherty AM, Hermez KM, Thomason ME. Developmental variation in regional brain iron and its relation to cognitive functions in childhood. Developmental Cogn Neurosci. 2018;34:18–26.

    Google Scholar 

  16. Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR. Oligodendrocytes and myelination: the role of iron. Glia. 2009;57:467–78.

    PubMed  Google Scholar 

  17. Haroutunian V, Katsel P, Roussos P, Davis K, Altshuler L, Bartzokis G. Myelination, oligodendrocytes, and serious mental illness. Glia. 2014;62:1856–77.

    CAS  PubMed  Google Scholar 

  18. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 2008;31:361–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry. 2004;161:398–413.

    PubMed  Google Scholar 

  20. Insel BJ, Schaefer CA, McKeague IW, Susser ES, Brown AS. Maternal iron deficiency and the risk of schizophrenia in offspring. Arch Gen Psychiatry. 2008;65:1136–44.

    PubMed  PubMed Central  Google Scholar 

  21. Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg RJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson imaging. 2005;23:1–25.

    CAS  PubMed  Google Scholar 

  22. Fukunaga M, Li TQ, van Gelderen P, de Zwart JA, Shmueli K, Yao B, et al. Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proc Natl Acad Sci USA. 2010;107:3834–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, Yen K, et al. Quantitative MR Imaging of Brain Iron: A Postmortem Validation Study. Radiology. 2010;257:455–62.

    PubMed  Google Scholar 

  24. Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. NeuroImage. 2012;62:1593–9.

    PubMed  Google Scholar 

  25. Deistung A, Schäfer A, Schweser F, Biedermann U, Turner R, Reichenbach JR. Toward in vivo histology: a comparison of quantitative susceptibility mapping (QSM) with magnitude-, phase-, and R2*-imaging at ultra-high magnetic field strength. NeuroImage. 2013;65:299–314.

    PubMed  Google Scholar 

  26. Xu M, Guo Y, Cheng J, Xue K, Yang M, Song X, et al. Brain iron assessment in patients with First-episode schizophrenia using quantitative susceptibility mapping. NeuroImage: Clin. 2021;31:102736.

    PubMed  Google Scholar 

  27. Sorensen HJ, Nielsen PR, Pedersen CB, Mortensen PB. Association between prepartum maternal iron deficiency and offspring risk of schizophrenia: population-based cohort study with linkage of Danish national registers. Schizophrenia Bull. 2011;37:982–7.

    Google Scholar 

  28. Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, et al. Association between psychiatric disorders and iron deficiency anemia among children and adolescents: a nationwide population-based study. BMC Psychiatry. 2013;13:161.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Lee H-S, Chao H-H, Huang W-T, Chen SC-C, Yang H-Y. Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis. BMC Psychiatry. 2020;20:216.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Saghazadeh A, Mahmoudi M, Shahrokhi S, Mojarrad M, Dastmardi M, Mirbeyk M, et al. Trace elements in schizophrenia: a systematic review and meta-analysis of 39 studies (N = 5151 participants). Nutr Rev. 2020;78:278–303.

    PubMed  Google Scholar 

  31. Kim SW, Stewart R, Park WY, Jhon M, Lee JY, Kim SY, et al. Latent Iron Deficiency as a Marker of Negative Symptoms in Patients with First-Episode Schizophrenia Spectrum Disorder. Nutrients. 2018;10:1707.

    PubMed  PubMed Central  Google Scholar 

  32. Casanova MF, Waldman IN, Kleinman JE. A postmortem quantitative study of iron in the globus pallidus of schizophrenic patients. Biol Psychiatry. 1990;27:143–9.

    CAS  PubMed  Google Scholar 

  33. Kornhuber J, Lange KW, Kruzik P, Rausch WD, Gabriel E, Jellinger K, et al. Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients. Biol Psychiatry. 1994;36:31–34.

    CAS  PubMed  Google Scholar 

  34. Lange KW, Kornhuber J, Kruzik P, Rausch WD, Gabriel E, Jellinger K, et al. Brain iron and schizophrenia. In: Riederer P, Youdim MBH, editors. Iron in Central Nervous System Disorders. Vienna: Springer; 1993. pp 37–43.

  35. Stevens JR. Neuropathology of schizophrenia. Arch Gen Psychiatry. 1982;39:1131–9.

    CAS  PubMed  Google Scholar 

  36. Stuber C, Morawski M, Schafer A, Labadie C, Wahnert M, Leuze C, et al. Myelin and iron concentration in the human brain: a quantitative study of MRI contrast. NeuroImage. 2014;93:95–106.

    PubMed  Google Scholar 

  37. Khodanovich M, Pishchelko A, Glazacheva V, Pan E, Akulov A, Svetlik M, et al. Quantitative Imaging of White and Gray Matter Remyelination in the Cuprizone Demyelination Model Using the Macromolecular Proton Fraction. Cells 2019;8:1204.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Underhill HR, Rostomily RC, Mikheev AM, Yuan C, Yarnykh VL. Fast bound pool fraction imaging of the in vivo rat brain: association with myelin content and validation in the C6 glioma model. NeuroImage. 2011;54:2052–65.

    PubMed  Google Scholar 

  39. Yarnykh VL. Fast macromolecular proton fraction mapping from a single off-resonance magnetization transfer measurement. Magn Reson Med. 2012;68:166–78.

    CAS  PubMed  Google Scholar 

  40. Samsonov AA, Alexander AL, Mossahebi P, Wu YC, Duncan ID, Field AS. Quantitative MR imaging of two-pool magnetization transfer model parameters in myelin mutant shaking pup. NeuroImage. 2012;62:1390–8.

    PubMed  Google Scholar 

  41. Yarnykh VL, Krutenkova EP, Aitmagambetova G, Repovic P, Mayadev A, Qian P, et al. Iron-Insensitive Quantitative Assessment of Subcortical Gray Matter Demyelination in Multiple Sclerosis Using the Macromolecular Proton Fraction. AJNR Am J Neuroradiol. 2018;39:618–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Callaghan MF, Helms G, Lutti A, Mohammadi S, Weiskopf N. A general linear relaxometry model of R1 using imaging data. Magn Reson Med. 2015;73:1309–14.

    PubMed  Google Scholar 

  43. Kendler KS, Lieberman JA, Walsh D. The Structured Interview for Schizotypy (SIS): a preliminary report. Schizophrenia Bull. 1989;15:559–71.

    CAS  Google Scholar 

  44. Walter EE, Fernandez F, Snelling M, Barkus E. Genetic consideration of schizotypal traits: A review. Front Psychol. 2016;7:1769.

    PubMed  PubMed Central  Google Scholar 

  45. Yarnykh VL. Time-efficient, high-resolution, whole brain three-dimensional macromolecular proton fraction mapping. Magn Reson Med. 2016;75:2100–6.

    CAS  PubMed  Google Scholar 

  46. Mossahebi P, Samsonov AA. Rapid and accurate variable flip angle T1 mapping with correction of on-resonance MT effects. In: Proceedings of the ISMRM. MelBourne: ISMRM annual Meeting; 2012. pp 4267.

  47. Kellner E, Dhital B, Kiselev VG, Reisert M. Gibbs-ringing artifact removal based on local subvoxel-shifts. Magn Reson Med. 2016;76:1574–81.

    PubMed  Google Scholar 

  48. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143–55.

    PubMed  PubMed Central  Google Scholar 

  49. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage. 2002;17:825–41.

    PubMed  Google Scholar 

  50. Veraart J, Novikov DS, Christiaens D, Ades-Aron B, Sijbers J, Fieremans E. Denoising of diffusion MRI using random matrix theory. NeuroImage. 2016;142:394–406.

    PubMed  Google Scholar 

  51. Veraart J, Fieremans E, Novikov DS. Diffusion MRI noise mapping using random matrix theory. Magn Reson Med. 2016;76:1582–93.

    CAS  PubMed  Google Scholar 

  52. Mossahebi P, Yarnykh VL, Samsonov A. Analysis and correction of biases in cross-relaxation MRI due to biexponential longitudinal relaxation. Magn Reson Med. 2014;71:830–8.

    PubMed  PubMed Central  Google Scholar 

  53. Samsonov AA, Mossahebi P, Anderson A, Velikina JV, Johnson KM, Johnson SC, et al. High Resolution, Motion Corrected Mapping of Macromolecular Proton Fraction (MPF). Clinically Acceptable Time Using 3D Undersampled Radials. In: Proceedings of the ISMRM. Milan: ISMRM annual Meeting; 2014. pp 3337.

  54. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55.

    CAS  PubMed  Google Scholar 

  55. Womer FY, Wang L, Alpert KI, Smith MJ, Csernansky JG, Barch DM, et al. Basal ganglia and thalamic morphology in schizophrenia and bipolar disorder. Psychiatry Res. 2014;223:75–83.

    PubMed  PubMed Central  Google Scholar 

  56. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006;8:118–27.

    PubMed  Google Scholar 

  57. Fortin JP, Cullen N, Sheline YI, Taylor WD, Aselcioglu I, Cook PA, et al. Harmonization of cortical thickness measurements across scanners and sites. NeuroImage. 2018;167:104–20.

    PubMed  Google Scholar 

  58. Fortin JP, Parker D, Tunc B, Watanabe T, Elliott MA, Ruparel K, et al. Harmonization of multi-site diffusion tensor imaging data. NeuroImage. 2017;161:149–70.

    PubMed  Google Scholar 

  59. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw. 2015;67:1–48.

    Google Scholar 

  60. Harkins KD, Xu J, Dula AN, Li K, Valentine WM, Gochberg DF, et al. The microstructural correlates of T1 in white matter. Magn Reson Med. 2016;75:1341–5.

    CAS  PubMed  Google Scholar 

  61. Rooney WD, Johnson G, Li X, Cohen ER, Kim SG, Ugurbil K, et al. Magnetic field and tissue dependencies of human brain longitudinal 1H2O relaxation in vivo. Magn Reson Med. 2007;57:308–18.

    CAS  PubMed  Google Scholar 

  62. Tukey JW. Exploratory data analysis. Massachusetts: Addison-Wesley; 1977.

  63. Lorio S, Kherif F, Ruef A, Melie-Garcia L, Frackowiak R, Ashburner J, et al. Neurobiological origin of spurious brain morphological changes: A quantitative MRI study. Hum Brain Mapp. 2016;37:1801–15.

    PubMed  PubMed Central  Google Scholar 

  64. Lorio S, Lutti A, Kherif F, Ruef A, Dukart J, Chowdhury R, et al. Disentangling in vivo the effects of iron content and atrophy on the ageing human brain. Neuroimage. 2014;103:280–9.

    CAS  PubMed  Google Scholar 

  65. Callaghan MF, Mohammadi S, Weiskopf N. Synthetic quantitative MRI through relaxometry modelling. NMR Biomed. 2016;29:1729–38.

    PubMed  PubMed Central  Google Scholar 

  66. Vymazal J, Urgosik D, Bulte JW. Differentiation between hemosiderin- and ferritin-bound brain iron using nuclear magnetic resonance and magnetic resonance imaging. Cell Mol Biol (Noisy-le-Gd). 2000;46:835–42.

    CAS  Google Scholar 

  67. Lee J, Shmueli K, Kang BT, Yao B, Fukunaga M, van Gelderen P, et al. The contribution of myelin to magnetic susceptibility-weighted contrasts in high-field MRI of the brain. NeuroImage. 2012;59:3967–75.

    PubMed  Google Scholar 

  68. Tamminga CA, Pearlson G, Keshavan M, Sweeney J, Clementz B, Thaker G. Bipolar and schizophrenia network for intermediate phenotypes: outcomes across the psychosis continuum. Schizophrenia Bull. 2014;40:S131–137.

    Google Scholar 

  69. Yamada Y, Matsumoto M, Iijima K, Sumiyoshi T. Specificity and Continuity of Schizophrenia and Bipolar Disorder: Relation to Biomarkers. Curr Pharm Des. 2020;26:191–200.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15–33.

    PubMed  PubMed Central  Google Scholar 

  71. Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M, et al. A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. JAMA psychiatry. 2017;74:1206–13.

    PubMed  PubMed Central  Google Scholar 

  72. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13–20.

    PubMed  Google Scholar 

  73. Bianco LE, Wiesinger J, Earley CJ, Jones BC, Beard JL. Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats. J Neurochem. 2008;106:205–15.

    CAS  PubMed  Google Scholar 

  74. Erikson KM, Jones BC, Hess EJ, Zhang Q, Beard JL. Iron deficiency decreases dopamine D1 and D2 receptors in rat brain. Pharm Biochem Behav. 2001;69:409–18.

    CAS  Google Scholar 

  75. Beard JL, Chen Q, Connor J, Jones BC. Altered monamine metabolism in caudate-putamen of iron-deficient rats. Pharm Biochem Behav. 1994;48:621–4.

    CAS  Google Scholar 

  76. Larsen B, Olafsson V, Calabro F, Laymon C, Tervo-Clemmens B, Campbell E, et al. Maturation of the human striatal dopamine system revealed by PET and quantitative MRI. Nat Commun. 2020;11:846.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Felt BT, Beard JL, Schallert T, Shao J, Aldridge JW, Connor JR, et al. Persistent neurochemical and behavioral abnormalities in adulthood despite early iron supplementation for perinatal iron deficiency anemia in rats. Behavioural brain Res. 2006;171:261–70.

    CAS  Google Scholar 

  78. Ortiz E, Pasquini JM, Thompson K, Felt B, Butkus G, Beard J, et al. Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models. J Neurosci Res. 2004;77:681–9.

    CAS  PubMed  Google Scholar 

  79. Byne W, Kidkardnee S, Tatusov A, Yiannoulos G, Buchsbaum MS, Haroutunian V. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophrenia Res. 2006;85:245–53.

    Google Scholar 

  80. Young KA, Manaye KF, Liang C-L, Hicks PB, German DC. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry. 2000;47:944–53.

    CAS  PubMed  Google Scholar 

  81. Mighdoll MI, Tao R, Kleinman JE, Hyde TM. Myelin, myelin-related disorders, and psychosis. Schizophrenia Res. 2015;161:85–93.

    Google Scholar 

  82. Hutcheson NL, Clark DG, Bolding MS, White DM, Lahti AC. Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. Psychiatry Res. 2014;221:6–12.

    PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Institutes of Health (R01MH108962 to ML and R01EB027087 to AS) and the Radiology Department at the NYU Grossman School of Medicine. We acknowledge our participants for their contribution. We thank Research Match and NAMI for supporting our recruitment efforts.

Author information

Authors and Affiliations

Authors

Contributions

The study was conceptualized by YVS and ML. Imaging data acquisition and processing was performed by YVS, FM, and ML. PS and AS provided expertise in MRI pulse sequence and quantitative parametric mapping. Recruitment of participants and clinical assessment were conducted with the help of HB and DCG. RA participated in statistical analysis and interpretation of results. YVS drafted the original manuscript with the help of ML. All authors were involved with manuscript review and editing.

Corresponding author

Correspondence to Yu Veronica Sui.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sui, Y.V., McKenna, F., Bertisch, H. et al. Decreased basal ganglia and thalamic iron in early psychotic spectrum disorders are associated with increased psychotic and schizotypal symptoms. Mol Psychiatry 27, 5144–5153 (2022). https://doi.org/10.1038/s41380-022-01740-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41380-022-01740-2

This article is cited by

Search

Quick links